Eutrepia is scaling rapidly and generating cash, supporting management's 2027 billion-dollar franchise target.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-03-06 |
| Length | 42 minutes |
| EPS | $0.15 |
| EPS consensus | $0.08 |
| Revenue | $92.0M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q3 FY25
Read the full Q4 FY25 earnings call transcript
All LQDA earnings · Back to LQDA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.